Because currently there has been no specific inhibitor of KCHIP1, developing anti-KCNIP1 RNA interference may be an option, and testing of this gene therapy in human clinical trials are warranted in the future to demonstrate the efficacy of inhibiting KCNIP1 expression to treat AF. Here, KCNIP1 is linked to atrial fibrillation.